Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OS TherapiesOSTX +1.64%10 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates OSTX with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 939 Biotechnology companies, OS Therapies ranks worse than 106496.17% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. OS Therapies's EBITDA for the
three
months ended in Mar. 2026 was $-10.20 Mil. OS Therapies's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, OS Therapies's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
OS Therapies (AMEX:OSTX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
OS Therapies EBITDA Margin % Related Terms
OS Therapies EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for OS Therapies's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTX vs RNTX, BSEM, PLRX: EBITDA Margin % Comparison
For the Biotechnology subindustry, OS Therapies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OS Therapies EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OS Therapies's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where OS Therapies's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OS Therapies (OSTX) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on OS Therapies and its competitors. According to the industry distribution chart, OS Therapies ranks #999999 out of 939 companies in the Biotechnology industry.
Is OS Therapies' EBITDA Margin % too high?
OS Therapies' current EBITDA Margin % is 0.00%. Based on the distribution chart, OS Therapies ranks #999999 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OS Therapies has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does OS Therapies' EBITDA Margin % compare to RNTX and BSEM?
According to the Biotechnology industry distribution chart, OS Therapies ranks #999999 out of 939 companies for EBITDA Margin %. This places OS Therapies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on OS Therapies and its competitors. OS Therapies's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OS Therapies stock overvalued right now?
OS Therapies (OSTX) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. OS Therapies' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For OS Therapies (OSTX), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.
10GF Score
Get the complete analysis for OSTX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTX has been successfully added to your 
